Preventing relapse before stem cell transplant for blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial checks if using advanced tests to find leftover cancer cells before a stem cell transplant can help prevent the disease from coming back. If you have a myeloid blood cancer, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older at the time of transplant.
- You need a diagnosis of a myeloid cancer like acute myeloid leukemia, myelodysplastic syndrome, or a related blood disorder.
- Before transplant, your doctors must use one of these tests to check for disease: a flow cytometry test, a genetic sequencing test (NGS), or a PCR test for known mutations.
- You must be able to understand and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests whether the drug interferon alfa can help prevent blood cancer from coming back after a stem cell transplant. It is for people with certain types of blood cancer (MDS or AML with a TP53 mutation) who had no detectable cancer cells when checked after transplant.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a stronger chemotherapy combination before a donor stem cell transplant for people with certain blood cancers (like AML, MDS, or CMML) that have spread to other parts of the body, such as the skin, testicles, or central nervous system. The goal is to see if this approach can improve outcomes for patients whose disease is in remission.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.